Efficacy and safety of liraglutide in Indian adolescents with obesity

Abstract

Summary Aim The aim of this study was to evaluate the efficacy and safety of liraglutide in adolescents with obesity. Materials and methods Patients ( n = 41) received injection liraglutide for at least 12 weeks and their pre‐baseline and post‐baseline characteristics were recorded and analysed. The key parameters analysed were weight, height, body mass index (BMI), fasting insulin and sugar, 1 h insulin and glucose, 2 h insulin and glucose, HbA1c, cholesterol, triglycerides, serum glutamic oxaloacetic transaminase, serum glutamic pyruvic transaminase, thyroid stimulating hormone and bone. Results There was a significant decrease ( p < 0.001) in body weight, BMI, fasting, 1 h post‐glucose tolerance and 2 h glucose tolerance. The changes from baseline to the end of study were for body weight − 6.5 ± 4.2 kg and BMI –2.35 ± 1.30 kg m −2 . Systolic blood pressure decreased from 119.25 ± 12.50 to 114.53 ± 9.53 mmHg and diastolic blood pressure from 70.69 ± 14.52 to 70.82 ± 8.85 mmHg. Liver enzymes had improved from 34.36 ± 12.23 (serum glutamic oxaloacetic transaminase), 38.08 ± 21.02 (serum glutamic pyruvic transaminase) to 33.52 ± 11.23 ( p = 0.03) and 33.99 ± 13.16 ( p = 0.01), respectively. Cholesterol and triglyceride had improved from 152.46 ± 24.74 and 124.41 ± 33.27 to 151.71 ± 23.46 ( p = 0.14) and 120.76 ± 26.22 ( p = 0.009), respectively. Conclusion In conclusion, treatment with liraglutide in adolescents with obesity offers an efficacious and safe alternative to patients who are not responding to other available modalities.

Liraglutide Effect on Weight, Glycated Hemoglobin, and Blood Pressure: A Single-Center Experience in the Eastern Province of Saudi Arabia

“…This study aimed to identify the efficacy of liraglutide on weight, HbA1c, and blood pressure in Saudi patients with T2D who attended KFUH and received liraglutide as add-on therapy to other antihyperglycemic agents. While similar studies have been conducted on other ethnic populations [ 14 , 15 ], this study is the first such study conducted in a Saudi population.…”

Childhood obesity: A review of current and future management options

“…The study showed that 51% of patients lost 5%–10% of their body weight and 23% lost over 10% 74 . The results also demonstrated a significant improvement in systolic blood pressure, insulin, glucose, HbA1c and lipid profile levels and liver function tests 74 …”

“…Evidence from trials of T2DM suggests that weight loss is achieved with higher doses of liraglutide, as shown by Kochar et al 74 The safety of such doses was established by Danne et al 75 in a double‐blind RCT which had a sample size of 21 adolescents. Liraglutide was given once daily for 5 weeks, with a maximal dose of 3 mg.…”

“…Liraglutide was shown to be well tolerated by all patients receiving the treatment 78 . Liraglutide has also shown promise as a potential therapeutic option in treatment‐resistant obesity by Kochar et al 74 Adolescents with obesity which was initially managed by lifestyle changes and then oral medications but had failed to achieve weight loss, were trialled on liraglutide for 12 weeks 74 . The study showed that 51% of patients lost 5%–10% of their body weight and 23% lost over 10% 74 .…”

“…Liraglutide has also shown promise as a potential therapeutic option in treatment‐resistant obesity by Kochar et al 74 Adolescents with obesity which was initially managed by lifestyle changes and then oral medications but had failed to achieve weight loss, were trialled on liraglutide for 12 weeks 74 . The study showed that 51% of patients lost 5%–10% of their body weight and 23% lost over 10% 74 . The results also demonstrated a significant improvement in systolic blood pressure, insulin, glucose, HbA1c and lipid profile levels and liver function tests 74 …”